Navigation Links
NeurogesX Reports First Quarter 2011 Results
Date:4/29/2011

e Act. Examples of such statements include but are not limited to: statements regarding expectations regarding the submission of the supplemental new drug application for label expansion of Qutenza, expectations regarding the Company's Phase 2 clinical trial of NGX-1998 and expected operating expenses, including moderated expense growth, for 2011.  Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to: difficulties or delays in the commercialization of Qutenza, including with respect to the successful marketing or manufacture and supply of Qutenza; physician or patient reluctance to use Qutenza, despite efforts and strategies to commercialize Qutenza; difficulties or delays in the further development of Qutenza for additional indications, including difficulties or delays in the submission of the sNDA for Qutenza; and difficulties or delays in the clinical development of NGX-1998.  For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission. NEUROGESX, INC.Condensed Consolidated Statements of Operations(in thousands, except share and per share information)Three Months EndedMarch 31,20112010 Net product revenue

$
575$
8212; Collaboration revenue

2,5951,786Total revenue

3,1701,786Operating expenses:Cost of goods sold

108—Research and development

3,9572,123Selling, general and administrative

10,2828,806Total operating expenses

14,34710,929Loss from operations

(11,177)(9,143)Interest income

278Interest expense

(2,200)(4)Other income (expense), net

(13)(24)Net loss

$
(13,363)$
(9,163)Basic and diluted net loss per share$
(0.75)$
(0.52)Shares used to compute basic and diluted net loss per share

17,870,34717,726,1
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. NeurogesX Receives Notice of Allowance for Patent Covering NGX-1998 Capsaicin Topical Liquid
2. NeurogesX Reports Fourth Quarter and Year-End 2010 Results
3. NeurogesX to Provide Qutenza® Launch Update
4. NeurogesX to Present at Two February Investor Conferences
5. NeurogesX Receives Qutenza®-Specific J-Code From Centers for Medicare and Medicaid Services (CMS)
6. NeurogesX Doses First Patient in Phase 2 Clinical Study of NGX-1998 Liquid Capsaicin Formulation
7. NeurogesX to Hold Conference Call to Discuss Third Quarter 2010 Results
8. NeurogesX to Present at Oppenheimer & Co Healthcare Conference
9. Although NeurogesX/Astellass Qutenza is Only Approved for Postherpetic Neuralgia, Surveyed U.S. Physicians are Likely to Prescribe It for All Neuropathic Pain Types
10. NeurogesX Appoints Seasoned Sales and Marketing Executive as New Board Director
11. NeurogesX Receives FDA Approval of Qutenza(TM) (capsaicin) 8% Patch for Treatment of Postherpetic Neuralgia (PHN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 19, 2014 Research and Markets has ... Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to ... purposes of this report, the human microbiome market is segmented ... microbiome market is expected to be valued as $294 million ... of 22.3% within the forecast period of 2019-2023. The market ...
(Date:9/19/2014)... UBM Medica US announces that  ... help oncologists and other clinicians gain a better understanding ... targeted therapies and immunotherapies, discusses some of the latest ... Every September, Blood Cancer Awareness Month ... blood cancers—helping to increase survival rates and improve the ...
(Date:9/19/2014)... , Sept. 19, 2014  Alere Inc. (NYSE: ... issued the following statement today in support of President ... "As the global leader in rapid diagnostics ... a national strategy to address the serious threat of ... with the Administration on initiatives to promote the development ...
Breaking Medicine Technology:Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2
... SEATTLE, April 27, 2011 Cell Therapeutics, Inc. ("CTI" ... accomplishments and financial results for the first quarter ended ... we raised $50 million through two financings, advanced pixantrone ... license from Chroma Therapeutics Ltd. ("Chroma") to co-develop and ...
... The Premier healthcare alliance, a network ... healthcare sites working together to achieve high quality, cost-effective ... leading provider of FDA-approved Superficial Radiotherapy committed to providing ... sufferers, a group purchasing agreement for the SRT-100™. Sensus ...
Cached Medicine Technology:Cell Therapeutics, Inc. Reports First Quarter Accomplishments and Financial Results 2Cell Therapeutics, Inc. Reports First Quarter Accomplishments and Financial Results 3Cell Therapeutics, Inc. Reports First Quarter Accomplishments and Financial Results 4Cell Therapeutics, Inc. Reports First Quarter Accomplishments and Financial Results 5Cell Therapeutics, Inc. Reports First Quarter Accomplishments and Financial Results 6Sensus Healthcare Awarded Sole Contract for Superficial Radiotherapy 2Sensus Healthcare Awarded Sole Contract for Superficial Radiotherapy 3
(Date:9/19/2014)... 19, 2014 “Copay coupons,” a drug ... brand drugs among patients with prescription drug coverage, may ... a new report from the Department of Health ... Federal anti-kickback laws prohibit suppliers from offering side-payments to ... federal government. , The report highlights that two recent ...
(Date:9/19/2014)... NY (PRWEB) September 19, 2014 On ... News at the Platinum PR and Top Places to ... in New York City. Camino received honorable mentions in ... Campaign” — for its work elevating Latina voices in ... incredible organization and be a part of its efforts ...
(Date:9/19/2014)... 2014 According to a report from ... blood-thinner Xarelto, named as defendants in several lawsuits filed ... moved the court to dismiss those suits because the ... connection with Philadelphia.* The cases include, for instance, Fontan ... Pa. Comm. Pls., Philadelphia Cty.), which was brought by ...
(Date:9/19/2014)... FRIDAY, Sept. 19, 2014 (HealthDay News) -- Although ... key health benefits, most middle-aged and older adults ... type of exercise, according to new research. ... the muscle-strengthening recommendations set by the Department of ... Strength is essential for promoting health and ...
(Date:9/19/2014)... MetroMD, a leading anti-ageing clinic has called its ... health. This therapy has grown tremendously across USA in the ... safe and dependable. It has far reaching benefits for ageing ... a very healthy and active lifestyle even beyond their middle ... senior therapist at MetroMD said, “HGH or Human Growth hormones ...
Breaking Medicine News(10 mins):Health News:PCMA: New OIG Report Cites Drug Manufacturer“Copay Coupon” Use in Medicare Part D 2Health News:Camino Public Relations Honored for Raising Latina Voices in National Health Care, Immigration Debates 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 3Health News:Adults Over 45 Not Meeting U.S. Muscle Strengthening Guidelines, Study Says 2Health News:MetroMD Announces Better HGH Therapy - the ‘God Particle’ of Human Health 2
... , This release is available in Spanish ... when we talk about a disease? What affects the ideas ... the University of Granada have developed a test ... disease. This advance will enable the development of clinical psychological ...
... (SACRAMENTO, Calif.) A study of the options for ... been treated for precancerous cervical lesions found that an ... strategy. Joy Melnikow, professor in the Department of ... screening strategies for the 500,000 American women diagnosed and ...
... WASHINGTON, Oct. 20 -- Scientists and engineers from around the ... Rochester, N.Y. next week to discuss some of the latest ... science, the development of new materials, and medicine. Journalists ... -- the 94th annual meeting of the Optical Society (OSA), ...
... Reporter , WEDNESDAY, Oct. 20 (HealthDay News) -- Researchers have discovered ... levels: Regular consumption of the world,s two most popular beverages may ... In fact, the latest research suggests that those who drink as ... may lower brain cancer risk by as much as 34 percent. ...
... The Los Angeles Biomedical Research Institute at Harbor-UCLA Medical ... Ridley-Thomas and Anne-Merelie Murrell, president of Giroux Glass Company, Inc., ... the Terranea Resort in Rancho Palos Verdes. Supervisor ... Excellence Award for Community Service. Mrs. Murrell will be ...
... Oct. 20 (HealthDay News) -- A combination of animal and ... therapy that could ultimately help in the treatment of major ... levels of a brain protein known as p11. The study ... of feelings of reward, pleasure and satisfaction with positive life ...
Cached Medicine News:Health News:The impact of chronic diseases on patients also depends on their perception of the disease 2Health News:Conventional, annual Pap smear cost-effective follow-up after cervical lesion treatment 2Health News:Conventional, annual Pap smear cost-effective follow-up after cervical lesion treatment 3Health News:Colorful brains, cooling lasers, disease-detecting lights and more 2Health News:Colorful brains, cooling lasers, disease-detecting lights and more 3Health News:Colorful brains, cooling lasers, disease-detecting lights and more 4Health News:Colorful brains, cooling lasers, disease-detecting lights and more 5Health News:Colorful brains, cooling lasers, disease-detecting lights and more 6Health News:Colorful brains, cooling lasers, disease-detecting lights and more 7Health News:Colorful brains, cooling lasers, disease-detecting lights and more 8Health News:Colorful brains, cooling lasers, disease-detecting lights and more 9Health News:Colorful brains, cooling lasers, disease-detecting lights and more 10Health News:Colorful brains, cooling lasers, disease-detecting lights and more 11Health News:Colorful brains, cooling lasers, disease-detecting lights and more 12Health News:Can Coffee, Tea Lower Brain Cancer Risk? 2Health News:Can Coffee, Tea Lower Brain Cancer Risk? 3Health News:LA BioMed honors 2 leaders 2Health News:Animal Study Explores Potential Gene Therapy for Depression 2Health News:Animal Study Explores Potential Gene Therapy for Depression 3
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Medicine Products: